0.319
price down icon9.55%   -0.0337
after-market Handel nachbörslich: .32 0.001 +0.31%
loading
Schlusskurs vom Vortag:
$0.3527
Offen:
$0.341
24-Stunden-Volumen:
4.59M
Relative Volume:
0.24
Marktkapitalisierung:
$5.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.89M
KGV:
-0.1261
EPS:
-2.53
Netto-Cashflow:
$-11.95M
1W Leistung:
+11.38%
1M Leistung:
-48.57%
6M Leistung:
-76.19%
1J Leistung:
-86.87%
1-Tages-Spanne:
Value
$0.3133
$0.3451
1-Wochen-Bereich:
Value
$0.2683
$0.661
52-Wochen-Spanne:
Value
$0.26
$2.58

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name
Firmenname
Plus Therapeutics Inc
Name
Telefon
737.255.7194
Name
Adresse
4200 MARATHON BLVD., AUSTIN, TX
Name
Mitarbeiter
21
Name
Twitter
@plustxinc
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
PSTV's Discussions on Twitter

Vergleichen Sie PSTV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PSTV
Plus Therapeutics Inc
0.319 4.87M 0 -12.89M -11.95M -2.53
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.00 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.82 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.282 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
85.54 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
483.07 65.36B 14.09B 4.50B 2.96B 39.28

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-17 Eingeleitet D. Boral Capital Buy
2021-01-25 Eingeleitet Ladenburg Thalmann Buy
2020-10-16 Eingeleitet Maxim Group Buy

Plus Therapeutics Inc Aktie (PSTV) Neueste Nachrichten

pulisher
Jun 05, 2025

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Ascendiant Capital raises Plus Therapeutics stock price target - Investing.com

Jun 05, 2025
pulisher
Jun 05, 2025

PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price T - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price Target | PSTV Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 03, 2025

Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks

Jun 03, 2025
pulisher
Jun 02, 2025

Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN

Jun 01, 2025
pulisher
May 31, 2025

Plus: Q1 Earnings Snapshot - New Haven Register

May 31, 2025
pulisher
May 30, 2025

Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year - TipRanks

May 30, 2025
pulisher
May 30, 2025

Plus Therapeutics (PSTV) Reports Financial Gains from Grant Reve - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Earnings Flash (PSTV) Plus Therapeutics Reports Q1 Loss $-1.19 Per Share, vs. FactSet Est of $-0.25 - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Plus Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 30, 2025
pulisher
May 30, 2025

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - The Manila Times

May 30, 2025
pulisher
May 30, 2025

PLUS THERAPEUTICS, INC. SEC 10-Q Report - TradingView

May 30, 2025
pulisher
May 28, 2025

Should Plus Therapeutics Inc (NASDAQ: PSTV) Investors Be Concerned? - Stocksregister

May 28, 2025
pulisher
May 27, 2025

DeFi Technologies Provides Monthly Corporate Update: Valour Reports C$1.18 Billion (US$819 Million) AUM, and Record Monthly Net Inflows of C$56 Million (US$38.8 Million) in December 2024 - The Globe and Mail

May 27, 2025
pulisher
May 25, 2025

3 No-Brainer Cloud Computing Stocks to Buy Right Now - The Globe and Mail

May 25, 2025
pulisher
May 24, 2025

Plus Therapeutics recives Nasdaq delinquency notice - MSN

May 24, 2025
pulisher
May 23, 2025

Plus Therapeutics, Inc. Receives Notification of Deficiency from - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Plus Therapeutics (PSTV) Faces Nasdaq Compliance Challenge - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Plus Therapeutics Faces Nasdaq Compliance Notice - TipRanks

May 23, 2025
pulisher
May 23, 2025

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q | PSTV Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Plus Therapeutics, Inc. Receives Notification of Deficiency - GlobeNewswire

May 23, 2025
pulisher
May 23, 2025

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - TradingView

May 23, 2025
pulisher
May 23, 2025

SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail

May 23, 2025
pulisher
May 20, 2025

Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment - MSN

May 20, 2025
pulisher
May 19, 2025

Plus Therapeutics Receives Nasdaq Delisting Notice - TipRanks

May 19, 2025
pulisher
May 19, 2025

Corpay Stock Jumps 25% in a Year: Here's What You Should Know - The Globe and Mail

May 19, 2025
pulisher
May 17, 2025

Tesla Stock Powers Up for Fourth Straight Week of Gains - The Globe and Mail

May 17, 2025
pulisher
May 15, 2025

Plus Therapeutics Delays Quarterly Report Filing - TipRanks

May 15, 2025
pulisher
May 15, 2025

Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - MSN

May 15, 2025
pulisher
May 14, 2025

Plus Therapeutics reports progress in CNS cancer therapy By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Plus Therapeutics (PSTV) Showcases Promising REYOBIQ Data at Con - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Plus Therapeutics Presents Promising ReSPECT Trial Data on REYOBIQ for Leptomeningeal Metastases at 2025 Nuclear Medicine and Neurooncology Conference - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Plus Therapeutics reports progress in CNS cancer therapy - Investing.com

May 14, 2025
pulisher
May 14, 2025

Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) - TradingView

May 14, 2025
pulisher
May 14, 2025

Plus Therapeutics (PSTV) Showcases Promising REYOBIQ Data at Conference | PSTV Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Plus Therapeutics (PSTV) Expected to Announce Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Leptomeningeal Metastases Pipeline 2025: Key Companies, MOA, - openPR.com

May 13, 2025
pulisher
May 08, 2025

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewswire

May 08, 2025
pulisher
May 07, 2025

Plus Therapeutics (NASDAQ:PSTV) Stock Rating Lowered by D Boral Capital - Defense World

May 07, 2025
pulisher
May 06, 2025

Plus Therapeutics (NASDAQ:PSTV) Given Hold Rating at D. Boral Capital - Defense World

May 06, 2025
pulisher
May 05, 2025

Plus Therapeutics (PSTV) Downgraded Amid Planned Reverse Stock S - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Colorectal Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa - Barchart.com

May 05, 2025
pulisher
May 05, 2025

This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga

May 05, 2025

Finanzdaten der Plus Therapeutics Inc-Aktie (PSTV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Plus Therapeutics Inc-Aktie (PSTV) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Hawkins Richard J
Director
Sep 13 '24
Buy
1.50
4,000
5,996
15,188
Hawkins Richard J
Director
Sep 12 '24
Buy
1.35
6,285
8,512
11,188
Petersen Greg
Director
Sep 11 '24
Buy
1.35
12,500
16,875
48,921
Clowes Howard
Director
Sep 11 '24
Buy
1.34
5,000
6,681
26,497
HEDRICK MARC H
Chief Executive Officer
Sep 10 '24
Buy
1.23
8,000
9,839
20,425
Sims Andrew John Hugh MacIntyr
Chief Financial Officer
Sep 10 '24
Buy
1.27
4,098
5,204
9,815
$1.15
price down icon 0.86%
$580.59
price up icon 1.24%
$308.00
price up icon 0.88%
$36.54
price up icon 1.27%
$4.8111
price up icon 1.29%
$483.07
price down icon 0.38%
Kapitalisierung:     |  Volumen (24h):